AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31709997 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 28857855 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter of condolence
Number of subjects: 52
Study 24714530 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb compression tights for 72 hours after the marathon run
Number of subjects: 24
Study 24714530 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment group received a single treatment of 15 minutes of sham ultrasound after the marathon run
Number of subjects: 24
Study 23664268 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (1 or 2 mA for 20 min, anode over the left dorsolateral prefrontal cortex, cathode right supraorbital cortex)
Number of subjects: 22
Study 23664268 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (placebo)
Number of subjects: 22
Study 20572473 — intervention group
Group type: EXPERIMENTAL
Intervention: VRDSRT (Virtual Reality Driving Simulation Rehabilitation Training)
Number of subjects: 11
Study 20572473 — intervention group
Group type: COMPARATOR
Intervention: Residential rehabilitation only (Control)
Number of subjects: 11
Study 17854995 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sucrose (25%; 0.5 ml/kg)
Number of subjects: 33
Study 17854995 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 33
Study 16005496 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 3 mg twice daily for 5 days
Number of subjects: 24
Study 16005496 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 24
Study 12834787 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed lunch (MIX)
Number of subjects: 36
Study 12834787 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat lunch (HF)
Number of subjects: 36
Study 12834787 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate lunch (HCHO)
Number of subjects: 36
Study 10787444 — intervention group
Group type: COMPARATOR
Intervention: Baseline diet (BL) - 39% kcal fat, 164 mg cholesterol/1000 kcal
Number of subjects: 14
Study 10787444 — intervention group
Group type: EXPERIMENTAL
Intervention: High trans stick margarine (SM)
Number of subjects: 14
Study 10787444 — intervention group
Group type: EXPERIMENTAL
Intervention: Low trans squeeze margarine (SQM)
Number of subjects: 14
Study 10787444 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium trans tub margarine (TM)
Number of subjects: 14
Study 10787444 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil (SO)
Number of subjects: 14
Study 10787444 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter (BT)
Number of subjects: 14
Study 10787444 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat baseline diet (BL)
Number of subjects: 14
Study 10787444 — intervention group
Group type: EXPERIMENTAL
Intervention: ASR-FC
Number of subjects: 14
Study 2107563 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human tissue-type plasminogen activator (rt-PA)
Number of subjects: 32
Study 2107563 — intervention group
Group type: COMPARATOR
Intervention: Urokinase (UK)
Number of subjects: 32
Study 313245 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant high-dose methotrexate with leucovorin rescue
Number of subjects: 39
Study 313245 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette‐Guérin by a multiple‐puncture technique
Number of subjects: 39
Study 313245 — intervention group
Group type: COMPARATOR
Intervention: Historical control patients treated with surgery alone
Number of subjects: 39
Study 313245 — intervention group
Group type: EXPERIMENTAL
Intervention: Current patients with grade III and IV lesions
Number of subjects: 39
Study 30736826 — intervention group
Group type: EXPERIMENTAL
Intervention: Yokukansan
Number of subjects: 220
Study 30736826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 27307057 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic teaching plus standardized patient simulation
Number of subjects: 94
Study 27307057 — intervention group
Group type: COMPARATOR
Intervention: Didactic teaching alone
Number of subjects: 94
Study 25315960 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-step posterior reconstruction technique
Number of subjects: 100
Study 25315960 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard technique)
Number of subjects: 100
Study 24393593 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.42 (Tetraspan)
Number of subjects: 798
Study 24393593 — intervention group
Group type: COMPARATOR
Intervention: Ringer's acetate
Number of subjects: 798
Study 24393593 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrastarch vs. crystalloid or albumin (systematic review)
Number of subjects: 798
Study 21902857 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean red meat (lamb)
Number of subjects: 36
Study 21902857 — intervention group
Group type: COMPARATOR
Intervention: Lean white meat (chicken)
Number of subjects: 36
Study 19015835 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (10 min moderate-intensity stationary cycling)
Number of subjects: 10
Study 19015835 — intervention group
Group type: COMPARATOR
Intervention: Control (passive seating for same duration)
Number of subjects: 10
Study 19015835 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise
Number of subjects: 10
Study 17239066 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure treatment for 4 weeks, 15 minutes, twice a day, five days a week.
Number of subjects: 31
Study 17239066 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (companionship and conversation) for 4 weeks after a treatment-free period.
Number of subjects: 31
Study 15898865 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only arm of a clinical trial
Number of subjects: 112
Study 11965102 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy and radiotherapy for good responders
Number of subjects: 104
Study 11965102 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy and radiotherapy for good responders with fixed arytenoid
Number of subjects: 104
Study 11965102 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy and radiotherapy for good responders with non-fixed arytenoid
Number of subjects: 104
Study 11965102 — intervention group
Group type: EXPERIMENTAL
Intervention: Arytenoid mobility before treatment
Number of subjects: 104
Study 9475538 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde autologous priming
Number of subjects: 60
Study 9475538 — intervention group
Group type: COMPARATOR
Intervention: Control (no retrograde autologous priming)
Number of subjects: 60
Study 7707457 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg/min erythromycin
Number of subjects: 15
Study 7707457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2530609 — intervention group
Group type: EXPERIMENTAL
Intervention: Duovent (fenoterol with ipratropium bromide)
Number of subjects: 17
Study 2530609 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 17
Study 7188826 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-containing (LC) dairy drink (4.5% lactose)
Number of subjects: 110
Study 7188826 — intervention group
Group type: COMPARATOR
Intervention: Lactose-free (LF) dairy drink
Number of subjects: 110
Study 30027819 — intervention group
Group type: EXPERIMENTAL
Intervention: Feasible gifts
Number of subjects: 0
Study 30027819 — intervention group
Group type: COMPARATOR
Intervention: Desirable gifts
Number of subjects: 0
Study 30027819 — intervention group
Group type: EXPERIMENTAL
Intervention: Giver focused on practicality or ease of use
Number of subjects: 0
Study 30027819 — intervention group
Group type: COMPARATOR
Intervention: Giver focused on overall quality
Number of subjects: 0
Study 28257412 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive direct coronary artery bypass (MIDCAB)
Number of subjects: 126
Study 28257412 — intervention group
Group type: COMPARATOR
Intervention: Off-pump CABG (OP-CABG)
Number of subjects: 126
Study 26941544 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic procedure on the stomach (CPT code 43650)
Number of subjects: 4116
Study 26941544 — intervention group
Group type: COMPARATOR
Intervention: Open gastrectomy (CPT code 43620‐2, 43631‐4)
Number of subjects: 4116
Study 24825528 — intervention group
Group type: EXPERIMENTAL
Intervention: House Calls (HC)
Number of subjects: 152
Study 24825528 — intervention group
Group type: COMPARATOR
Intervention: Group Based (GB)
Number of subjects: 152
Study 24825528 — intervention group
Group type: COMPARATOR
Intervention: Individual Counseling (IC)
Number of subjects: 152
Study 22275463 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality therapy
Number of subjects: 18
Study 22275463 — intervention group
Group type: COMPARATOR
Intervention: Conventional arm therapy
Number of subjects: 18
Study 20040895 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 gxkg‐1 NaHCO3
Number of subjects: 8
Study 20040895 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 gxkg‐1 NaHCO3
Number of subjects: 8
Study 20040895 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 gxkg‐1 NaHCO3
Number of subjects: 8
Study 20040895 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Morning Dosage (SMD) NaHCO3
Number of subjects: 8
Study 20040895 — intervention group
Group type: COMPARATOR
Intervention: Single Evening Dosage (SED) NaHCO3
Number of subjects: 8
Study 20040895 — intervention group
Group type: COMPARATOR
Intervention: Consecutive Evening Dosage (CED) NaHCO3
Number of subjects: 8
Study 18549844 — intervention group
Group type: EXPERIMENTAL
Intervention: GM group (patients with geographic miss)
Number of subjects: 1557
Study 18549844 — intervention group
Group type: EXPERIMENTAL
Intervention: LGM group (longitudinal geographic miss)
Number of subjects: 1557
Study 18549844 — intervention group
Group type: COMPARATOR
Intervention: no-GM group (patients without geographic miss)
Number of subjects: 1557
Study 18549844 — intervention group
Group type: COMPARATOR
Intervention: no-LGM group (no longitudinal geographic miss)
Number of subjects: 1557
Study 16022094 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic disease
Number of subjects: 1864
Study 16022094 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1864
Study 16022094 — intervention group
Group type: EXPERIMENTAL
Intervention: Kt/V > or = 2.0
Number of subjects: 1864
Study 11827923 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty (PTCA)
Number of subjects: 298
Study 11827923 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational atherectomy followed by balloon angioplasty (ROTA)
Number of subjects: 298
Study 10419079 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg daily
Number of subjects: 530
Study 10419079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study 10419079 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and Placebo (combined)
Number of subjects: 530
Study 7579063 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis (HD)
Number of subjects: 702
Study 7579063 — intervention group
Group type: COMPARATOR
Intervention: Continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 702
Study 7579063 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy controls
Number of subjects: 702
Study 7579063 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between HD and CAPD
Number of subjects: 702
Study 7579063 — intervention group
Group type: EXPERIMENTAL
Intervention: HD and CAPD patients
Number of subjects: 702
Study 7579063 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with high-molecular-weight apolipoprotein(a) isoforms
Number of subjects: 702
Study 2145347 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) infusion (0.1 microgram/kg/min during 30 minutes)
Number of subjects: 8
Study 2145347 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol infusion (0.13 microgram/kg/min)
Number of subjects: 8
Study 2145347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6109102 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate
Number of subjects: 75
Study 6109102 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 75
Study 31101534 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin and S-1
Number of subjects: 741
Study 31101534 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and S-1
Number of subjects: 741
Study 27761582 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg bolus followed by 75 mg daily
Number of subjects: 60
Study 27761582 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg daily (no bolus)
Number of subjects: 60
Study 25867814 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (90-minute treadmill walk at 50% maximal oxygen uptake)
Number of subjects: 10
Study 25867814 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 10
Study 24169063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide hydrofluoroalkane nasal aerosol (CIC‐HFA) at 74 micrograms
Number of subjects: 294
Study 24169063 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate aqueous nasal spray (MFNS) at 200 micrograms
Number of subjects: 294
Study 24169063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide hydrofluoroalkane nasal aerosol (CIC‐HFA)
Number of subjects: 294
Study 21251625 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 619
Study 21251625 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 619
Study 19517198 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed lateral sphincterotomy (LS)
Number of subjects: 63
Study 19517198 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerine ointment (GTN)
Number of subjects: 63
Study 19517198 — intervention group
Group type: COMPARATOR
Intervention: Injection of botulinum toxin (BTX)
Number of subjects: 63
Study 18007569 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ziprasidone (20 mg) after an 8-hour fast
Number of subjects: 22
Study 18007569 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ziprasidone (40 mg) after an 8-hour fast
Number of subjects: 22
Study 18007569 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ziprasidone (80 mg) after an 8-hour fast
Number of subjects: 22
Study 18007569 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ziprasidone (40 mg) with a high-fat meal (60% fat)
Number of subjects: 22
Study 18007569 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ziprasidone (40 mg) with a moderate-fat meal (30% fat)
Number of subjects: 22
Study 18007569 — intervention group
Group type: COMPARATOR
Intervention: Oral ziprasidone (40 mg) under fasting conditions
Number of subjects: 22
Study 14718823 — intervention group
Group type: EXPERIMENTAL
Intervention: TriVex (powered phlebectomy)
Number of subjects: 141
Study 14718823 — intervention group
Group type: COMPARATOR
Intervention: Conventional varicose vein surgery
Number of subjects: 141
Study 14718823 — intervention group
Group type: EXPERIMENTAL
Intervention: TriVex
Number of subjects: 141
Study 11292231 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg melatonin
Number of subjects: 40
Study 11292231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9041947 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (8 gm/day for 28 days)
Number of subjects: 0
Study 9041947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7933370 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (home visits and center-based schooling)
Number of subjects: 985
Study 7933370 — intervention group
Group type: COMPARATOR
Intervention: Follow-up only group
Number of subjects: 985
Study 3216031 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg controlled-release tablet every 8 hours with cimetidine 300 mg four times a day for 7 days
Number of subjects: 10
Study 3216031 — intervention group
Group type: COMPARATOR
Intervention: Pentoxifylline 400 mg controlled-release tablet every 8 hours without cimetidine
Number of subjects: 10
Study 3216031 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg controlled-release tablet every 8 hours with cimetidine
Number of subjects: 10
Study 31931853 — intervention group
Group type: EXPERIMENTAL
Intervention: Guhong injection
Number of subjects: 260
Study 31931853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 29040947 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine XR
Number of subjects: 388
Study 29040947 — intervention group
Group type: COMPARATOR
Intervention: chlorpromazine
Number of subjects: 388
Study 28874596 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax ginseng extract (PG) 400 mg twice daily for 28 days
Number of subjects: 127
Study 28874596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 28874596 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax ginseng extract (PG)
Number of subjects: 127
Study 26230399 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mm lateral wedge insole
Number of subjects: 36
Study 26230399 — intervention group
Group type: COMPARATOR
Intervention: 6 mm medial wedge insole
Number of subjects: 36
Study 26230399 — intervention group
Group type: EXPERIMENTAL
Intervention: KAAI increase or decrease groups
Number of subjects: 36
Study 26230399 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute % change in KAAI
Number of subjects: 36
Study 24565129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (Group IVM)
Number of subjects: 60
Study 24565129 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (Group EM)
Number of subjects: 60
Study 24565129 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine-bupivacaine (Group EMB)
Number of subjects: 60
Study 24565129 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine-ropivacaine (Group EMR)
Number of subjects: 60
Study 20478681 — intervention group
Group type: COMPARATOR
Intervention: Walking Advice (WA)
Number of subjects: 304
Study 20478681 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Therapy (SET)
Number of subjects: 304
Study 20478681 — intervention group
Group type: EXPERIMENTAL
Intervention: SET with Feedback
Number of subjects: 304
Study 20478681 — intervention group
Group type: EXPERIMENTAL
Intervention: SET
Number of subjects: 304
Study 18443313 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 40 mg IV
Number of subjects: 10
Study 18443313 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) IV
Number of subjects: 10
Study 16061499 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention
Number of subjects: 1518
Study 16061499 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1518
Study 11914314 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10344353 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (810 mg daily)
Number of subjects: 80
Study 10344353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 9180981 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution (RL, n = 10)
Number of subjects: 30
Study 9180981 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethylstarch 6% (HEA, n = 10)
Number of subjects: 30
Study 9180981 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline (NaCl, n = 10)
Number of subjects: 30
Study 1919149 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 50 mg/kg administered intravenously immediately before IPHP
Number of subjects: 18
Study 1919149 — intervention group
Group type: COMPARATOR
Intervention: Control (no cimetidine)
Number of subjects: 18
Study 1919149 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 18
Study 1919149 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study 6818581 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 60
Study 6818581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31809215 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS
Number of subjects: 112
Study 31809215 — intervention group
Group type: COMPARATOR
Intervention: CECT
Number of subjects: 112
Study 31809215 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 112
Study 29880243 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap administered 3-4 weeks before MCV4 and PCV13
Number of subjects: 166
Study 29880243 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap administered concomitantly with MCV4 and PCV13
Number of subjects: 166
Study 29880243 — intervention group
Group type: EXPERIMENTAL
Intervention: MCV4 and PCV13 administered 3-4 weeks before Tdap
Number of subjects: 166
Study 27498916 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (by face mask inhalation or aerosol inhaler)
Number of subjects: 60
Study 27498916 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone (by inhaler)
Number of subjects: 60
Study 27498916 — intervention group
Group type: COMPARATOR
Intervention: Saline inhalation (control)
Number of subjects: 60
Study 24285251 — intervention group
Group type: EXPERIMENTAL
Intervention: SMOFlipid 20%
Number of subjects: 40
Study 24285251 — intervention group
Group type: COMPARATOR
Intervention: MCT/LCT (Lipovenoes 20%)
Number of subjects: 40
Study 22258622 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification-based treatment
Number of subjects: 156
Study 22258622 — intervention group
Group type: COMPARATOR
Intervention: Usual physical therapy care
Number of subjects: 156
Study 19175871 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV)
Number of subjects: 924
Study 19175871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 924
Study 16846547 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized purified flavonoid fraction (MPFF), six tablets per day for 4 days followed by four tablets per day for 3 days
Number of subjects: 90
Study 16846547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 12744364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vancomycin (2 g/day, four infusions/day)
Number of subjects: 10